Literature DB >> 19491826

A randomized, double-blind, placebo-controlled trial of rifaximin, a nonabsorbable antibiotic, in the treatment of tropical enteropathy.

Indi Trehan1, Robert J Shulman, Ching-Nan Ou, Kenneth Maleta, Mark J Manary.   

Abstract

OBJECTIVES: Tropical enteropathy is characterized by an increased urinary lactulose-to-mannitol (L:M) ratio on a site-specific sugar absorption test and is associated with increased intestinal permeability and decreased nutrient absorptive capacity. The etiology of tropical enteropathy is postulated to be intestinal bacterial overgrowth. This study tested the hypothesis that treatment with a nonabsorbable, broad-spectrum antibiotic, rifaximin, reduces the L:M ratio in rural Malawian children, among whom tropical enteropathy is common.
METHODS: All children aged 3-5 years from one village were enrolled in a randomized, double-blind, placebo-controlled trial of treatment with rifaximin for 7 days. The L:M ratio was measured before and after treatment, and the change in the L:M ratio was the primary outcome. Secondary outcomes were changes in the urinary sucrose-to-lactulose (SUC:L) and sucralose-to-lactulose (SCL:L) ratios, as well as changes in the fractions of each test sugar recovered in the urine.
RESULTS: A total of 144 children participated in this study, of whom 76% had an elevated L:M ratio on enrollment (L:M > or = 0.10). Children who received rifaximin did not show an improvement in their L:M ratio compared with those who received placebo (-0.01+/-0.12 vs. 0.02+/-0.16, respectively, P=0.51, mean+/-s.d.), nor were there significant differences between the two groups in excretion of lactulose, mannitol, sucralose, or sucrose, or in the SUC:L and SCL:L ratios.
CONCLUSIONS: Rifaximin had no effect on the tropical enteropathy of 3-5-year-old Malawian children, suggesting that small-bowel bacterial overgrowth is not an important etiological factor in this condition.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19491826      PMCID: PMC2758482          DOI: 10.1038/ajg.2009.270

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  37 in total

Review 1.  Commensal host-bacterial relationships in the gut.

Authors:  L V Hooper; J I Gordon
Journal:  Science       Date:  2001-05-11       Impact factor: 47.728

Review 2.  Tropical malabsorption.

Authors:  B S Ramakrishna; S Venkataraman; A Mukhopadhya
Journal:  Postgrad Med J       Date:  2006-12       Impact factor: 2.401

Review 3.  The measurement and clinical significance of intestinal permeability.

Authors:  Christopher W Teshima; Jon B Meddings
Journal:  Curr Gastroenterol Rep       Date:  2008-10

4.  High dosage rifaximin for the treatment of small intestinal bacterial overgrowth.

Authors:  E Scarpellini; M Gabrielli; C E Lauritano; A Lupascu; G Merra; G Cammarota; I A Cazzato; G Gasbarrini; A Gasbarrini
Journal:  Aliment Pharmacol Ther       Date:  2007-04-01       Impact factor: 8.171

5.  Rifaximin treatment of pathogen-negative travelers' diarrhea.

Authors:  Herbert L DuPont; Robert Haake; David N Taylor; Charles D Ericsson; Zhi-Dong Jiang; Pablo C Okhuysen; Robert Steffen
Journal:  J Travel Med       Date:  2007 Jan-Feb       Impact factor: 8.490

6.  Intestinal permeability, mucosal injury, and growth faltering in Gambian infants.

Authors:  P G Lunn; C A Northrop-Clewes; R M Downes
Journal:  Lancet       Date:  1991-10-12       Impact factor: 79.321

7.  Lactulose-mannitol intestinal permeability test in children with diarrhea caused by rotavirus and cryptosporidium. Diarrhea Working Group, Peru.

Authors:  Y Zhang; B Lee; M Thompson; R Glass; R I Cama; D Figueroa; R Gilman; D Taylor; C Stephenson
Journal:  J Pediatr Gastroenterol Nutr       Date:  2000-07       Impact factor: 2.839

8.  Increased gastrointestinal permeability and gut inflammation in children with functional abdominal pain and irritable bowel syndrome.

Authors:  Robert J Shulman; Michelle N Eakin; Danita I Czyzewski; Monica Jarrett; Ching-Nan Ou
Journal:  J Pediatr       Date:  2008-06-09       Impact factor: 4.406

9.  A large-scale operational study of home-based therapy with ready-to-use therapeutic food in childhood malnutrition in Malawi.

Authors:  Zachary Linneman; Danielle Matilsky; MacDonald Ndekha; Micah J Manary; Ken Maleta; Mark J Manary
Journal:  Matern Child Nutr       Date:  2007-07       Impact factor: 3.092

10.  Efficacy of rifaximin, a nonabsorbed oral antibiotic, in the treatment of small intestinal bacterial overgrowth.

Authors:  Marek Majewski; Savio C Reddymasu; Sandra Sostarich; Pernilla Foran; Richard W McCallum
Journal:  Am J Med Sci       Date:  2007-05       Impact factor: 2.378

View more
  45 in total

Review 1.  Early child growth: how do nutrition and infection interact?

Authors:  Kathryn G Dewey; Daniel R Mayers
Journal:  Matern Child Nutr       Date:  2011-10       Impact factor: 3.092

2.  Therapeutic role of rifaximin in inflammatory bowel disease: clinical implication of human pregnane X receptor activation.

Authors:  Jie Cheng; Yatrik M Shah; Xiaochao Ma; Xiaoyan Pang; Toshiya Tanaka; Tatsuhiko Kodama; Kristopher W Krausz; Frank J Gonzalez
Journal:  J Pharmacol Exp Ther       Date:  2010-07-13       Impact factor: 4.030

3.  Environmental Enteric Dysfunction Is Associated With Altered Bile Acid Metabolism.

Authors:  Richard D Semba; Marta Gonzalez-Freire; Ruin Moaddel; Indi Trehan; Kenneth M Maleta; Mohammed Khadeer; Maria Isabel Ordiz; Luigi Ferrucci; Mark J Manary
Journal:  J Pediatr Gastroenterol Nutr       Date:  2017-04       Impact factor: 2.839

Review 4.  Pregnane X receptor as a target for treatment of inflammatory bowel disorders.

Authors:  Jie Cheng; Yatrik M Shah; Frank J Gonzalez
Journal:  Trends Pharmacol Sci       Date:  2012-05-18       Impact factor: 14.819

Review 5.  Enteropathies in the developing world: neglected effects on global health.

Authors:  Andrew Prendergast; Paul Kelly
Journal:  Am J Trop Med Hyg       Date:  2012-05       Impact factor: 2.345

6.  Alanyl-glutamine promotes intestinal epithelial cell homeostasis in vitro and in a murine model of weanling undernutrition.

Authors:  Priscilla M Ueno; Reinaldo B Oriá; Elizabeth A Maier; Marjorie Guedes; Orleancio G de Azevedo; David Wu; Tara Willson; Simon P Hogan; Aldo A M Lima; Richard L Guerrant; D Brent Polk; Lee A Denson; Sean R Moore
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2011-07-28       Impact factor: 4.052

Review 7.  Environmental enteropathy: critical implications of a poorly understood condition.

Authors:  Poonum S Korpe; William A Petri
Journal:  Trends Mol Med       Date:  2012-05-25       Impact factor: 11.951

Review 8.  Immunogenicity and efficacy of oral vaccines in developing countries: lessons from a live cholera vaccine.

Authors:  Myron M Levine
Journal:  BMC Biol       Date:  2010-10-04       Impact factor: 7.431

9.  Hyperamylasemia is associated with increased intestinal permeability in patients undergoing diagnostic oral double-balloon enteroscopy.

Authors:  Nan Feng; Jun Dai; Hong Lu; Xiao-Bo Li; Yun-Jie Gao; Zhi-Zheng Ge
Journal:  World J Gastroenterol       Date:  2014-01-14       Impact factor: 5.742

Review 10.  Environmental Enteric Dysfunction in Children.

Authors:  Sana Syed; Asad Ali; Christopher Duggan
Journal:  J Pediatr Gastroenterol Nutr       Date:  2016-07       Impact factor: 2.839

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.